105 related articles for article (PubMed ID: 1550082)
21. [Therapy-related acute non-lymphocytic leukemia (M2) with 7;11 chromosome translocation induced into complete remission by low dose cytosine arabinoside and cytarabine ocfosfate therapy].
Shikoshi K; Shikoshi K; Niitsu N; Takada M; Umeda M
Nihon Ronen Igakkai Zasshi; 1994 Jun; 31(6):468-71. PubMed ID: 8078212
[TBL] [Abstract][Full Text] [Related]
22. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients.
Stone RM; Maguire M; Goldberg MA; Antin JH; Rosenthal DS; Mayer RJ
Blood; 1988 Mar; 71(3):690-6. PubMed ID: 3422828
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Tallman MS; Appelbaum FR; Amos D; Goldberg RS; Livingston RB; Mortimer J; Weiden PL; Thomas ED
J Clin Oncol; 1987 Jun; 5(6):918-26. PubMed ID: 3585446
[TBL] [Abstract][Full Text] [Related]
24. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
25. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
[TBL] [Abstract][Full Text] [Related]
26. Etoposide in remission induction of adult acute myeloid leukemia.
Leoni F; Ciolli S; Patriarchi S; Morfini M; Rossi Ferrini P
Acta Haematol; 1990; 83(2):82-5. PubMed ID: 2106200
[TBL] [Abstract][Full Text] [Related]
27. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
Bow EJ; Kilpatrick MG; Scott BA; Clinch JJ; Cheang MS
Cancer; 1994 Jul; 74(1):52-60. PubMed ID: 8004583
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission.
Dahl GV; Kalwinsky DK; Mirro J; Look AT; Pui CH; Murphy SB; Mason C; Ruggiero M; Schell M; Johnson FL
J Clin Oncol; 1990 Feb; 8(2):295-303. PubMed ID: 2299372
[TBL] [Abstract][Full Text] [Related]
29. Treatment of "poor risk" acute nonlymphocytic leukemia with continuously infused low-dose cytosine arabinoside.
Balaban EP; Cox JV; Schneider NR; Harth CA; Haley BB; Sheehan R; Frenkel EP
Am J Hematol; 1988 Oct; 29(2):79-84. PubMed ID: 3189306
[TBL] [Abstract][Full Text] [Related]
30. [A regimen of DATV in the treatment of acute nonlymphocytic leukemia with high complete remission rate].
Lou FD; Zhou Q; Meng FY
Zhonghua Nei Ke Za Zhi; 1992 Mar; 31(3):146-8, 187. PubMed ID: 1395925
[TBL] [Abstract][Full Text] [Related]
31. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
[TBL] [Abstract][Full Text] [Related]
32. Remission induction in children with acute non-lymphocytic leukemia using cytosine arabinoside and doxorubicin or daunorubicin: a report from the Childrens Cancer Study Group.
Buckley JD; Lampkin BC; Nesbit ME; Bernstein ID; Feig SA; Kersey JH; Piomelli S; Kim T; Hammond GD
Med Pediatr Oncol; 1989; 17(5):382-90. PubMed ID: 2677628
[TBL] [Abstract][Full Text] [Related]
33. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
[TBL] [Abstract][Full Text] [Related]
34. Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.
Dekker AW; Nieuwenhuis HK; Verdonck LF
Cancer; 1990 May; 65(9):1891-4. PubMed ID: 2372760
[TBL] [Abstract][Full Text] [Related]
35. [Evaluation of 58 patients with acute leukemia].
Sasaki A; Tsukaguchi M
Gan To Kagaku Ryoho; 1992 Aug; 19(9):1303-7. PubMed ID: 1503484
[TBL] [Abstract][Full Text] [Related]
36. Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients.
Hartmann F; Jacobs G; Gotto H; Schwamborn J; Pfreundschuh M
Leuk Lymphoma; 2001 Jul; 42(3):347-55. PubMed ID: 11699399
[TBL] [Abstract][Full Text] [Related]
37. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
Stein RS; Vogler WR; Winton EF; Cohen HJ; Raney MR; Bartolucci A
Leuk Res; 1990; 14(10):895-903. PubMed ID: 2259226
[TBL] [Abstract][Full Text] [Related]
38. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
Linkesch W; Michlmayr G; Gerhartz H; Illinger H; König H; Düllmann J; Keilhauer R; Moldrzyk D
Onkologie; 1989 Feb; 12(1):8-10. PubMed ID: 2654791
[TBL] [Abstract][Full Text] [Related]
39. [Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].
Koyama S; Itou S; Shibata A
Rinsho Ketsueki; 1990 Nov; 31(11):1891-2. PubMed ID: 2287079
[TBL] [Abstract][Full Text] [Related]
40. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.
Maslak PG; Weiss MA; Berman E; Yao TJ; Tyson D; Golde DW; Scheinberg DA
Leukemia; 1996 Jan; 10(1):32-9. PubMed ID: 8558934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
